CN1706499A - Zine replenisher with palygorskite or mentmorillonite carrier and its prepn and usage - Google Patents
Zine replenisher with palygorskite or mentmorillonite carrier and its prepn and usage Download PDFInfo
- Publication number
- CN1706499A CN1706499A CN 200510049876 CN200510049876A CN1706499A CN 1706499 A CN1706499 A CN 1706499A CN 200510049876 CN200510049876 CN 200510049876 CN 200510049876 A CN200510049876 A CN 200510049876A CN 1706499 A CN1706499 A CN 1706499A
- Authority
- CN
- China
- Prior art keywords
- zinc
- montmorillonitum
- paligorskite
- carrier
- ore pulp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052625 palygorskite Inorganic materials 0.000 title abstract description 6
- 239000011701 zinc Substances 0.000 claims abstract description 83
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 66
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 66
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 22
- 235000010755 mineral Nutrition 0.000 claims abstract description 22
- 239000011707 mineral Substances 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 238000005342 ion exchange Methods 0.000 claims abstract description 10
- 238000003756 stirring Methods 0.000 claims description 34
- 229940091251 zinc supplement Drugs 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 230000018044 dehydration Effects 0.000 claims description 15
- 238000006297 dehydration reaction Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 230000003203 everyday effect Effects 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 150000003751 zinc Chemical class 0.000 claims description 7
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 5
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 4
- 230000002354 daily effect Effects 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- 239000011592 zinc chloride Substances 0.000 claims description 4
- 235000005074 zinc chloride Nutrition 0.000 claims description 4
- 229960001763 zinc sulfate Drugs 0.000 claims description 4
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 3
- 229910000323 aluminium silicate Inorganic materials 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 230000037452 priming Effects 0.000 claims description 3
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- 239000004927 clay Substances 0.000 claims description 2
- 239000000391 magnesium silicate Substances 0.000 claims description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 2
- 235000019792 magnesium silicate Nutrition 0.000 claims description 2
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000004575 stone Substances 0.000 claims description 2
- 239000001117 sulphuric acid Substances 0.000 claims 1
- 235000011149 sulphuric acid Nutrition 0.000 claims 1
- 206010048259 Zinc deficiency Diseases 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 11
- 230000003578 releasing effect Effects 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 239000011573 trace mineral Substances 0.000 abstract description 4
- 235000013619 trace mineral Nutrition 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000003111 delayed effect Effects 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 6
- 239000004744 fabric Substances 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 238000004062 sedimentation Methods 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 239000011229 interlayer Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005341 cation exchange Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000002734 clay mineral Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- JPIJQSOTBSSVTP-GBXIJSLDSA-N D-threonic acid Chemical compound OC[C@@H](O)[C@H](O)C(O)=O JPIJQSOTBSSVTP-GBXIJSLDSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- JPIJQSOTBSSVTP-STHAYSLISA-N L-threonic acid Chemical compound OC[C@H](O)[C@@H](O)C(O)=O JPIJQSOTBSSVTP-STHAYSLISA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 229960005488 aceglutamide Drugs 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960000892 attapulgite Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000004300 dark adaptation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940056902 l- threonic acid Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000021062 nutrient metabolism Nutrition 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 102000029752 retinol binding Human genes 0.000 description 1
- 108091000053 retinol binding Proteins 0.000 description 1
- 235000015598 salt intake Nutrition 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229940071566 zinc glycinate Drugs 0.000 description 1
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is zinc replenisher with palygorskite or mentmorillonite carrier and its preparation and usage. The zinc replenisher is palygorskite or mentmorillonite containing active zinc in 9-11 wt%. The preparation process includes ion exchange reaction to implant zinc as one kind of trace element into the lattice of palygorskite or mentmorillonite to form palygorskite or mentmorillonite containing active Zn ion. The carrier mineral has delayed releasing effect and excellent biocompatibility, so that the zinc replenisher has less irritation and side effect on gastrointestinal tract and high Zn ion absorption. Replenishing zinc element can prevent and treat various diseases caused by zinc deficiency.
Description
Technical field
The present invention relates to a kind of is the zinc supplement agent and the preparation using method thereof of carrier with Paligorskite, Montmorillonitum.
Background technology
Zinc is a kind of trace element of needed by human, also is trace element the abundantest in the cell.The adult needs 10～15mg/d, and the child needs 10mg/d approximately.Zinc is distributed in each histoorgan of human body, and organ content such as retina, choroid, prostate are maximum, and pancreas, liver, kidney, muscle also contain more zinc.According to the Chinese Academy of Medical Sciences zinc content in 18 provinces and cities' preschooler hairs is measured, about 60% child's zinc content is lower than normal value.Zinc is mainly from food in the human body, and the meals of population of China constitute substantially based on cereals, and the zinc content of cereals is generally lower.Therefore, the zinc intake deficiency is than general phenomenon, and is particularly outstanding in the child.
Zinc participates in the synthetic of the interior many enzymes of body.There is the activity of nearly 200 kinds of enzymes relevant in the human body with zinc, as archaeal dna polymerase, RNA synzyme, the many dehydrogenases relevant with nutrient metabolism; Transport the relevant carbonic anhydrase of oxygen and carbon dioxide function with erythrocyte; The alkali phosphatase relevant with bone growth and development, etc.
Cause the factor of human body zinc deficiency to mainly contain: the one, the intake deficiency, corn and fruit and vegerable group food zinc content are low, and this is the main cause of the general zinc deficiency of China's population; The 2nd, the increase of demand increases the demand of zinc as anemia of pregnant woman and suckling woman, infant and juvenile because the requirement of growth promoter increases the easier zinc deficiency of these crowds to the zinc demand; The 3rd, zinc is lost increase in the body, and hunger, burn, wound and major operation patient can cause that urinating zinc drains increase because disorganization decomposes for a long time; In addition, nephropathy, chronic blood loss, diabetes, parasitic infection and chronic alcoholism person can make the interior zinc of body lose.
Zinc deficiency is many-sided to the negative effect of body.The one, to the influence of growth promoter and tissue regeneration, zinc wide participation nucleic acid and proteinic metabolism, the activity reduction of zinc dependence enzyme in the human body behind the zinc deficiency, hinder the normal replication and the differentiation of cell, the early stage performance that studies confirm that period of development child zinc deficiency is growth retardation or stagnation, zinc deficiency can hinder normal cartilage to generate and calcification process, influences upgrowth and development of children.Zinc deficiency person collagen protein is synthetic not enough, and wound healing is bad, easily infects.The 2nd, to the influence of sexual organ and sexual function.Zinc deficiency can cause male secondary sex characters and female sex organs hypoevolutism, and youth of both sexes all have hypogonadism phenomenon, sexual disorder.The 3rd, the interaction between zinc and the hormone, it is synthetic that zinc not only participates in insulin, and the effect of stable insulin structure arranged, zinc deficiency can make insulin degraded aggravation, cause in the blood that insulin level descends and the glucose utilization string is reduced, glucose tolerance descends, and most with urinating the patient with zinc malabsorption.Zinc deficiency also causes the output of body internal thymus element and the function of activity and T cell to reduce, and body immunity goes down.The 4th, zinc deficiency can cause that the concentration of retinol binding protein in the blood reduces, and the influence tissue makes people's vision and dark adaptation ability drop to the utilization of vitamin A.
The zinc supplement medicine of Shi Yonging is a zinc sulfate the earliest, but owing to gastrointestinal mucosa being had side effect such as zest causes nausea, vomiting, less at present use.Therefore, people attempt using the organic zinc preparation in recent years, comprise zinc acetate, zinc citrate, orotic acid one arginine zinc, zinc glycyrrhetate, zinc gluconate, L-aspartase zinc, L-zn lysine chelated, zinc glycinate, L-threonic acid THREONIC ACID. zinc, zinc fructose diphosphate, aceglutamide zinc, etc.The preparation complexity of organic zinc, expensive, and most effect still can not be affirmed.
Paligorskite and Montmorillonitum are suitable for as Zn
2+Ionophore is relevant with their crystal chemistry composition and crystalline texture.The theoretical molecular formula of Paligorskite is:
Mg
5Si
8O
20(OH)
2(OH
2)
44H
2The O wherein position of Mg often has other bivalence and Tricationic displacement.The crystalline texture of Paligorskite has hole, intracrystalline tunnel, and Mg and other foreign ion are exposed to the tunnel hole surface, are easy to by Zn
2+Ion exchange.
Montmorillonitum is a kind of layer structure clay mineral that has, and chemical analysis is an aluminosilicate, and chemical structural formula can be write as:
(M
+ X+yNH
2O) (R
3+ 2-yR
2+ y) (Si
4-xAl
x) O
10(OH)
2M in the formula
+Represent monovalent cation, as: Na
+, Li
+And K
+R
2+, R
3+Represent the bivalence and the Tricationic of interlayer position respectively, as: Ca
2+, Mg
2+, Fe
2+And Fe
3+The interlayer cation of Montmorillonitum is easy to by other cation replacement, is Zn
2+Ionic ideal carrier.
With Paligorskite or Montmorillonitum as Zn
2+Ionic carrier helps slowing down the side effect that may exist, and can utilize the bioaffinity of carrier mineral simultaneously, improves its absorbance.
Summary of the invention
The purpose of this invention is to provide a kind of is zinc supplement agent and the preparation and the using method of carrier with Paligorskite, Montmorillonitum.
Of the present invention is that the zinc supplement agent of carrier is a kind of Paligorskite, Montmorillonitum that contains commutative zinc ion with Paligorskite, Montmorillonitum, and by weight percentage, the content of zinc element in carrier mineral is 9～11%.
This is that the preparation method of the zinc supplement agent of carrier may further comprise the steps with Paligorskite, Montmorillonitum:
1) separate purification Paligorskite, Montmorillonitum according to a conventional method, the acid solution that the mineral after purifying and weight are 3～5 times mixes, and stirs, carry out priming reaction, centrifugal then or filtering means dehydration is after water cleans, add water again and stir, make concentration and be 3～20% suspension ore pulp;
2) with zinc content be the zinc salt of Paligorskite, Montmorillonitum weight 9～11%, the water-soluble solution that is configured to is slowly poured ore pulp into when stirring, carry out ion-exchange reactions;
3) detecting the pH value of ore pulp, is 0.5～2 mole NaOH solution adjusting with concentration, and making slurry pH is 8.0～9.5;
4) with methods such as precipitation, centrifugal or filter pressings, make pulp dewatering;
5) shine dry or dry being lower than under 80 ℃ of temperature the step 4) gains are cool naturally, be ground to, obtain water content less than 10% powder body less than 300 orders;
In preparation method of the present invention:
Said Paligorskite is a kind of magnesium silicate mineral with layer chain structure, and said Montmorillonitum is a kind of aluminium silicate mineral with layer structure, and they are clay, mud stone, shale or loose massive ore in natural output form.
It is 1～5 mole hydrochloric acid, nitric acid or sulfuric acid solution that but mineral are activated working concentration, considers from combined factors such as environment, costs, recommends to use hydrochloric acid, and the weight ratio of mineral and acid solution was controlled at 1: 3 to 1: 5.Zinc salt is selected one or more in the hydrate of zinc chloride, zinc nitrate and zinc sulfate or these salts for use.
Tablet or powder are made in the zinc supplement agent that said method makes, be applicable to human oral.Child's gram every day 0.05～0.1, per day for adults 0.1～0.15 gram, anemia of pregnant woman and old people's gram every day 0.15～0.20 divide 2～3 inferior to taking half an hour ante cibum.
Advantage of the present invention is:
1) utilize the cation exchange capacity (CEC) of natural Paligorskite, Montmorillonitum to carry divalent zinc ion, production cost is low;
2) carrier mineral Paligorskite, Montmorillonitum and gastrointestinal tract mucous affinity height have improved Zn greatly
2+Ion absorption in vivo rate has also reduced excretion and environment residual quantity simultaneously;
3) slowly releasing effect of mineral has improved Zn
2+Ionic safety in utilization;
4) carrier mineral has the advantages that water-swellable scatters, and is easy to use.
The specific embodiment
Select for use Paligorskite and Montmorillonitum as Zn
2+Ionic carrier is because their layer chain, layered crystal structure have slow releasing function to cation on the one hand, has reduced Zn
2+The moment concentration of ion in gastrointestinal tract has improved safety in utilization; These two kinds of mineral all have good bioaffinity in addition, are easy to the surface attached to gastrointestinal mucosa, thereby improve Zn
2+Ion absorption in vivo rate
The technology of separating purification Paligorskite (having another name called attapulgite) and Montmorillonitum (having another name called bentonite) from natural crystal is well-known, and it comprises pulverizings, pull an oar and make suspension, classification collection less than the granule of 2 μ etc.Paligorskite after the purification, Montmorillonitum are light green color, light yellow clay mineral, have good dispersibility in water.
Preparation method is carried out in two steps, and the first step uses acid solution that carrier mineral is activated, and makes the cation of mineral octahedral site and interlayer position be equipped with dripping taking out of, forms lattice vacancy.Said acid solution is that concentration is 1～5 mole hydrochloric acid, nitric acid or sulfuric acid solution, recommends to use hydrochloric acid, and the weight ratio of mineral and acid solution was controlled at 1: 3 to 1: 5, stirs to make the two evenly mixed, and course of reaction should continue to stir.Priming reaction can at room temperature carry out, and if any cheap thermal source, also can heat ore pulp.Heating can be shortened the response time.
Second step was used zinc solution, made the Zn in the solution
2+Ca in ion exchange Paligorskite, the montmorillonite mineral lattice
2+, Mg
2+, Na
+With other interlayer cation, or insert in the lattice vacancy.Said zinc salt can be selected one or more in zinc chloride, zinc nitrate and the zinc sulfate for use, and the present invention recommends to use zinc chloride.The zinc salt consumption should make zinc element be equivalent to 9～11% of Montmorillonitum weight, and recommendation is 10%.
In manufacturing process of the present invention, it is not very strict that the water yield that relevant step is added requires, and under the prerequisite that equipment such as stirring, mixing and spray drying can run well, should reduce water, to reduce production costs as far as possible.Stirring and mixing can be selected conventional equipment for use, and the blended time limit is advisable can form obviously uniform slurry.
The pH value of regulating and controlling ore pulp is one of key of the present invention.Zn
2+After ion-exchange reactions finishes, should detect the pH value of ore pulp,, make pH values of pulp between 8.0～9.5 if its pH＜8 then add an amount of NaOH solution.Regulating the purpose of pH value, is to make Zn remaining in the solution
2+Ion precipitation is in order to avoid contaminated environment.After regulating pH, should be once more that flowsheet of slurry agitation is even.
The dewatering process of ore pulp, but treatment in accordance with local conditions select for use filter cloth filtration, sedimentation tank, centrifuge or pressure filter to dewater.
The dehydration back should notice that bake out temperature must not surpass 90 ℃ if use the drying plant drying, preferably is controlled at below 80 ℃, and the too high meeting of temperature undergoes phase transition Montmorillonitum, loses cation exchange capacity (CEC), Zn
2+Ion also loses activity thereupon.
Year zinc Paligorskite after the oven dry, Montmorillonitum are hard bulk, can select for use conventional equipment crushing grinding to granularity to be not more than 300 orders.Be final products after the pack.
Need accurately to measure the zinc content of final products, and clearly be identified in the outer package.
Further specify the present invention below in conjunction with instantiation.
Embodiment 1:
With the Paligorskite is the zinc supplement agent and the preparation thereof of carrier, may further comprise the steps:
1. take by weighing 10Kg and separate the Paligorskite of purifying, adding 50Kg concentration is 5 moles hydrochloric acid, stirs in agitator; At room temperature carry out ion-exchange reactions 24 hours, and continue to stir therebetween, after the centrifuge dehydration then, water cleaning, stirring, centrifugal 1～2 time, add 90Kg water again and stir, make concentration and be 10% Paligorskite suspension ore pulp;
2. take by weighing 2.08 kilograms of ZnCl
2(containing zinc element 1Kg), dissolve in the premium on currency, when stirring, ZnCl
2Solution is slowly poured in the agitator that fills ore pulp.Allow ore pulp and zinc-containing solution in agitator, react six hours, during stirred 3～5 minutes every one hour so that ore pulp keeps suspended state.
3. slowly adding concentration and be 1 mole NaOH solution when stirring, is 8.0 until the pH value of ore pulp.
4. ore pulp leaves standstill diel in agitator, makes the Paligorskite natural sedimentation, absorbs the supernatant with siphonage, and precipitate is poured on further dehydration on the filter cloth.Ore pulp after the dehydration is divided into fritter with chipper or spades, and oven dry under 70 ℃ of environment of temperature, broken, grinding make product granularity less than 300 orders, pack.It is the zinc supplement agent of carrier that products obtained therefrom is with the Paligorskite, and zinc element content was 10% (every gram product contains 100 milligrams of zinc element) in this product.
Embodiment 2:
With the Montmorillonitum is the zinc supplement agent and the preparation thereof of carrier, may further comprise the steps:
1. take by weighing 10Kg and separate the Montmorillonitum of purifying, adding 30Kg concentration is 3 moles hydrochloric acid, stirs in agitator; At room temperature carry out ion-exchange reactions at least 12 hours, continue to stir therebetween, after the centrifuge dehydration then, water cleaning, stirring, centrifugal 1～2 time, add 90Kg water again and stir, make concentration and be 10% Montmorillonitum suspension ore pulp;
2. take by weighing 2.08 KgZnCl
2(containing zinc element 1Kg), dissolve in the premium on currency, when stirring, ZnCl
2Solution is slowly poured in the agitator that fills ore pulp.Allow ore pulp and zinc-containing solution in agitator, react six hours, during stirred 3～5 minutes every one hour so that ore pulp keeps suspended state.
3. slowly adding concentration and be 1 mole NaOH solution when stirring, is 9.5 until the pH value of ore pulp.
4. ore pulp leaves standstill diel in agitator, make the Montmorillonitum natural sedimentation, absorb the supernatant with siphonage, precipitate is poured on further dehydration on the filter cloth, the ore pulp after the dehydration is divided into fritter with chipper or spades, oven dry under 80 ℃ of environment of temperature, broken, grinding, make product granularity less than 300 orders, pack, it is the zinc supplement agent of carrier that products obtained therefrom is with the Montmorillonitum, zinc element content was 10% (every gram product contains 100 milligrams of zinc element) in this product.
Embodiment 3:
With the Paligorskite is the zinc supplement agent and the preparation thereof of carrier, may further comprise the steps:
1. take by weighing 10Kg and separate the Paligorskite of purifying with conventional method, adding 50Kg concentration is 3 moles hydrochloric acid, stirs in agitator; At room temperature carry out ion-exchange reactions 24 hours, and continue to stir therebetween, after the centrifuge dehydration then, water cleaning, stirring, centrifugal 1～2 time, add 90Kg water again and stir, make concentration and be 10% Paligorskite suspension ore pulp;
2. take by weighing 1.88 kilograms of ZnCl
2(containing zinc element 0.9Kg), dissolve in the premium on currency, when stirring, ZnCl
2Solution is slowly poured in the agitator that fills ore pulp.Allow ore pulp and zinc-containing solution in agitator, react six hours, during stirred 3～5 minutes every one hour so that ore pulp keeps suspended state.
3. the pH that records ore pulp with pH meter is 4.5.Slowly adding concentration and be 0.5 mole NaOH solution when stirring, is 9.0 until pH value.
4. ore pulp leaves standstill diel in agitator, makes the Paligorskite natural sedimentation, absorbs the supernatant with siphonage, and precipitate is poured on further dehydration on the filter cloth.Ore pulp after the dehydration is divided into fritter with chipper or spades, and oven dry under 70 ℃ of environment of temperature, broken, grinding make product granularity less than 300 orders, pack.It is the zinc supplement agent of carrier that products obtained therefrom is with the Paligorskite, and zinc element content was 9% (every gram product contains 90 milligrams of zinc element) in this product.
Embodiment 4:
With the Montmorillonitum is the zinc supplement agent and the preparation thereof of carrier, may further comprise the steps:
1. take by weighing 10Kg and separate the Montmorillonitum of purifying, adding 30Kg concentration is 5 moles hydrochloric acid, stirs in agitator; At room temperature carry out ion-exchange reactions at least 12 hours, continue to stir therebetween, after the centrifuge dehydration then, water cleaning, stirring, centrifugal 1～2 time, add 90Kg water again and stir, make concentration and be 10% Montmorillonitum suspension ore pulp;
2. take by weighing 2.29 KgZnCl
2(containing zinc element 1.1Kg), dissolve in the premium on currency, when stirring, ZnCl
2Solution is slowly poured in the agitator that fills ore pulp.Allow ore pulp and zinc-containing solution in agitator, react six hours, during stirred 3～5 minutes every one hour so that ore pulp keeps suspended state.
3. slowly adding concentration and be 1 mole NaOH solution when stirring, is 8.5 until the pH value of ore pulp.
4. ore pulp leaves standstill diel in agitator, make the Montmorillonitum natural sedimentation, absorb the supernatant with siphonage, precipitate is poured on further dehydration on the filter cloth, the ore pulp after the dehydration is divided into fritter with chipper or spades, oven dry under 80 ℃ of environment of temperature, broken, grinding, make product granularity less than 300 orders, pack, it is the zinc supplement agent of carrier that products obtained therefrom is with the Montmorillonitum, zinc element content was 11% (every gram product contains 110 milligrams of zinc element) in this product.
Embodiment 5:
With the Paligorskite is the zinc supplement agent of the using method of the zinc supplement agent of carrier: embodiment 1 and embodiment 2 preparations, and compacting weighs the tablet of 0.05 gram in flakes, and every contains 5 milligrams on zinc, for daily zinc supplement, 1～4 of every day, divides 2～3 inferior to half an hour ante cibum.
Embodiment 6:
With the Montmorillonitum is the zinc supplement agent of the using method of the zinc supplement agent of carrier: embodiment 3 preparations, and compacting weighs the tablet of 0.05 gram in flakes, and every contains 4.5 milligrams on zinc, for daily zinc supplement, 1～4 of every day, divides 2～3 inferior to half an hour ante cibum.
Embodiment 6:
With the Montmorillonitum is the zinc supplement agent of the using method of the zinc supplement agent of carrier: embodiment 3 preparations, and compacting weighs the tablet of 0.05 gram in flakes, and every contains 5.5 milligrams on zinc, for daily zinc supplement, 1～4 of every day, divides 2～3 inferior to half an hour ante cibum.
The invention provides a kind of is zinc supplement agent and the preparation and the using method of carrier with Paligorskite, Montmorillonitum.This invention utilizes the cation exchange capacity (CEC) of natural minerals to carry divalent zinc ion, and production cost is low; Carrier mineral and gastrointestinal tract mucous affinity height have improved Zn greatly
2+Ion absorption in vivo rate has also reduced excretion and environment residual quantity simultaneously; The slowly releasing effect of mineral has improved Zn
2+Ionic safety in utilization; Carry the zinc Paligorskite, Montmorillonitum has the advantages that water-swellable scatters, and is easy to use.Based on the prepared zinc supplement agent of the present invention, can be by slow releasing function for the human or animal provide essential trace element zinc, alleviated and directly taken the various side effect that inorganic zinc salt, zincate bring, increased the absorbance of zinc.The zinc element that is replenished can prevent and treat the various diseases that causes because of zinc deficiency.
Claims (6)
1. one kind is the zinc supplement agent of carrier with Paligorskite, Montmorillonitum, it is characterized in that it is a kind of Paligorskite, Montmorillonitum that contains commutative zinc ion, and by weight percentage, the content of zinc element in Paligorskite, Montmorillonitum is 9～11%.
2. according to claim 1 is the preparation method of the zinc supplement agent of carrier with Paligorskite, Montmorillonitum, it is characterized in that it may further comprise the steps:
1) separate purification Paligorskite, Montmorillonitum according to a conventional method, the acid solution that the mineral after purifying and weight are 3～5 times mixes, and stirs, carry out priming reaction, centrifugal then or filtering means dehydration is after water cleans, add water again and stir, make concentration and be 3～20% suspension ore pulp;
2) with zinc content be the zinc salt of Paligorskite, Montmorillonitum weight 9～11%, the water-soluble solution that is configured to is slowly poured ore pulp into when stirring, carry out ion-exchange reactions;
3) detecting the pH value of ore pulp, is 0.5～2 mole NaOH solution adjusting with concentration, and making slurry pH is 8.0～9.5;
4) with methods such as precipitation, centrifugal or filter pressings, make pulp dewatering;
5) shine dry or dry being lower than under 80 ℃ of temperature the step 4) gains are cool naturally, be ground to, obtain water content less than 10% powder body less than 300 orders;
3. a kind of according to claim is the zinc supplement agent of carrier with Paligorskite, Montmorillonitum, it is characterized in that said Paligorskite is a kind of magnesium silicate mineral with layer chain structure, said Montmorillonitum is a kind of aluminium silicate mineral with layer structure, and they are clay, mud stone, shale or loose massive ore in natural output form.
4. according to claim 2 is the preparation method of the zinc supplement agent of carrier with Paligorskite, Montmorillonitum, it is characterized in that said acid solution is that concentration is 1～5 mole hydrochloric acid, nitric acid or sulphuric acid.
5. according to claim 2 is the preparation method of the zinc supplement agent of carrier with Paligorskite, Montmorillonitum, it is characterized in that said zinc salt is the hydrate of zinc chloride, zinc nitrate and zinc sulfate or these salts.
6. according to claim 1 is the using method of the zinc supplement agent of carrier with Paligorskite, Montmorillonitum, it is characterized in that being applicable to human daily zinc supplement, dosage control child's gram every day 0.05～0.1, per day for adults 0.1～0.15 gram, anemia of pregnant woman and old people's gram every day 0.15～0.20 divide 2～3 inferior to taking half an hour ante cibum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510049876 CN1706499A (en) | 2005-05-30 | 2005-05-30 | Zine replenisher with palygorskite or mentmorillonite carrier and its prepn and usage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510049876 CN1706499A (en) | 2005-05-30 | 2005-05-30 | Zine replenisher with palygorskite or mentmorillonite carrier and its prepn and usage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1706499A true CN1706499A (en) | 2005-12-14 |
Family
ID=35580730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510049876 Pending CN1706499A (en) | 2005-05-30 | 2005-05-30 | Zine replenisher with palygorskite or mentmorillonite carrier and its prepn and usage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1706499A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103340897A (en) * | 2013-07-12 | 2013-10-09 | 乔敏 | Zinc-based montmorillonite medicine for treating peptic ulcer and preparation method thereof |
| CN109349431A (en) * | 2018-12-21 | 2019-02-19 | 美泰克（天津）矿物有限公司 | A kind of preparation method of anti-diarrhea additive for feed for porkets |
| CN109691596A (en) * | 2019-02-02 | 2019-04-30 | 浙江大学 | A kind of broiler chicken intestinal mucosa renovation agent |
-
2005
- 2005-05-30 CN CN 200510049876 patent/CN1706499A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103340897A (en) * | 2013-07-12 | 2013-10-09 | 乔敏 | Zinc-based montmorillonite medicine for treating peptic ulcer and preparation method thereof |
| CN103340897B (en) * | 2013-07-12 | 2015-12-02 | 山东司邦得制药有限公司 | Zinc-base montmorillonite medicine for the treatment of peptic ulcer and preparation method thereof |
| CN109349431A (en) * | 2018-12-21 | 2019-02-19 | 美泰克（天津）矿物有限公司 | A kind of preparation method of anti-diarrhea additive for feed for porkets |
| CN109349431B (en) * | 2018-12-21 | 2021-12-17 | 美泰克（天津）矿物有限公司 | Preparation method of diarrhea-preventing suckling pig feed additive |
| CN109691596A (en) * | 2019-02-02 | 2019-04-30 | 浙江大学 | A kind of broiler chicken intestinal mucosa renovation agent |
| CN109691596B (en) * | 2019-02-02 | 2021-10-15 | 浙江大学 | Broiler chicken intestinal mucosa repairing agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4689605B2 (en) | Flocculant, method for producing the same and method for using the same | |
| EA017083B1 (en) | Compound comprising crystalline lanthanum oxycarbonate, method of making lanthanum oxycarbonate, use thereof for treating hyperphosphatemia | |
| CN106219720B (en) | Improve water quality, strengthen immunity, beneficial to composite mineral substance crystal of cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN1706499A (en) | Zine replenisher with palygorskite or mentmorillonite carrier and its prepn and usage | |
| CN110272032B (en) | Preparation method of magnesium-doped hydroxyapatite drug-loaded microspheres | |
| CN1164276C (en) | Method of in vitro culturing medicine ox gallstone with natural ox gall | |
| CN1058887A (en) | The production technology scheme of activation mineral health food mineralizing agent | |
| CN100351261C (en) | Crystalline glucosamine sulphate metal salts and its preparation method | |
| CN1895282A (en) | Calcium supplementary agent and its preparation | |
| CN1857304A (en) | Iodine replenisher with control released iodine and its preparing method and use | |
| CN1321646C (en) | Oral zinc reinforcing agent using hydrotalcite as carrier, its preparation and using method thereof | |
| CN1861091A (en) | Load type molecular iodine complementary agent, and its prepn. method and use | |
| CN101284016A (en) | Bezoar vitro bred and solid oral preparation containing the bezoar | |
| CN1688511A (en) | Rare earth metal compounds, methods of making, and methods of using the same | |
| CN1186989C (en) | Chromium element feed additive using montmorillonite as carrier, its preparation method and application | |
| CN1381270A (en) | Ca-supplementing instant composite polypeptide powder and its preparing process | |
| JP2660906B2 (en) | Method for producing sea urchin-derived calcium and composition containing easily absorbable calcium obtained by this method | |
| CN101156663A (en) | Organism organic selenium honey health food and its preparation | |
| CN1813794A (en) | Lead-removing growth-assisting tablet and its preparing method | |
| CN1686558A (en) | Chromium supplementing agent using palygorskite or montmorillonite as carrier, its preparation and use method | |
| CN106631848B (en) | Preparation method of lysine chelated calcium by taking bay scallop shells as calcium source | |
| CN1401329A (en) | Oral Selenium supplement agent using bimetallic oxide as carrier, and preparing process and use method thereof | |
| CN1775733A (en) | Calcium nervonate and its preparing method and use | |
| CN111840572A (en) | Preparation method of zinc-doped hydroxyapatite drug-loaded microspheres | |
| CN1857308A (en) | Zinc replenisher with control released zinc and its preparing method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |